CN101237886A - 产生重量减轻的组合物 - Google Patents

产生重量减轻的组合物 Download PDF

Info

Publication number
CN101237886A
CN101237886A CNA2006800271079A CN200680027107A CN101237886A CN 101237886 A CN101237886 A CN 101237886A CN A2006800271079 A CNA2006800271079 A CN A2006800271079A CN 200680027107 A CN200680027107 A CN 200680027107A CN 101237886 A CN101237886 A CN 101237886A
Authority
CN
China
Prior art keywords
chemical compound
compositions
group
naltrexone
individuality
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800271079A
Other languages
English (en)
Chinese (zh)
Inventor
加里·托尔夫森
安东尼·A·麦金尼
米歇尔·S·希金
约翰·M·麦考尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orexigen Therapeutics Inc
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of CN101237886A publication Critical patent/CN101237886A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2006800271079A 2005-07-27 2006-07-24 产生重量减轻的组合物 Pending CN101237886A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70287705P 2005-07-27 2005-07-27
US60/702,877 2005-07-27

Publications (1)

Publication Number Publication Date
CN101237886A true CN101237886A (zh) 2008-08-06

Family

ID=37198787

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800271079A Pending CN101237886A (zh) 2005-07-27 2006-07-24 产生重量减轻的组合物

Country Status (12)

Country Link
US (1) US20070117827A1 (https=)
EP (1) EP1907005A1 (https=)
JP (1) JP2009502931A (https=)
KR (1) KR20080042092A (https=)
CN (1) CN101237886A (https=)
AU (1) AU2006275914A1 (https=)
BR (1) BRPI0613911A2 (https=)
CA (1) CA2614539A1 (https=)
IL (1) IL188442A0 (https=)
MX (1) MX2008001136A (https=)
RU (1) RU2007147609A (https=)
WO (1) WO2007016108A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110740751A (zh) * 2017-03-28 2020-01-31 Ldn制药有限公司 用于治疗肺癌的结合物
US11351165B2 (en) 2017-03-28 2022-06-07 LDN Pharma Limited Agent that increases the expression of the opioid kappa 1 for the treatment of cancer

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
EP1617832B1 (en) * 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DK2089005T3 (da) 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
EP2214672B1 (en) 2007-10-18 2012-10-17 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
KR101717145B1 (ko) 2008-05-20 2017-03-16 노이로제스엑스, 인코포레이티드 간보호제 아세트아미노펜 공통 프로드러그
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
SMT202500474T1 (it) 2010-12-03 2026-01-12 Nalpropion Pharmaceuticals Llc Aumento della biodisponibilità farmacologica nella terapia con naltrexone
CN110893181A (zh) 2012-06-06 2020-03-20 纳丙药业有限责任公司 治疗超重和肥胖症的方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
EP1617832B1 (en) * 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110740751A (zh) * 2017-03-28 2020-01-31 Ldn制药有限公司 用于治疗肺癌的结合物
US11304943B2 (en) 2017-03-28 2022-04-19 LDN Pharma Limited Combination for use in the treatment of lung cancer
US11351165B2 (en) 2017-03-28 2022-06-07 LDN Pharma Limited Agent that increases the expression of the opioid kappa 1 for the treatment of cancer

Also Published As

Publication number Publication date
BRPI0613911A2 (pt) 2011-02-22
US20070117827A1 (en) 2007-05-24
MX2008001136A (es) 2008-03-13
KR20080042092A (ko) 2008-05-14
WO2007016108B1 (en) 2007-05-10
WO2007016108A1 (en) 2007-02-08
EP1907005A1 (en) 2008-04-09
CA2614539A1 (en) 2007-02-08
IL188442A0 (en) 2008-04-13
AU2006275914A1 (en) 2007-02-08
JP2009502931A (ja) 2009-01-29
RU2007147609A (ru) 2009-09-10

Similar Documents

Publication Publication Date Title
CN101370488B (zh) 增加胰岛素敏感性的组合物
CN101237886A (zh) 产生重量减轻的组合物
CN1784221B (zh) 影响体重减轻的组合物
AU2005206139B2 (en) Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US20060058293A1 (en) Combination of bupropion and a second compound for affecting weight loss
US20100179129A1 (en) Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
TW200803901A (en) Methods of treating anxiety disorders
HK1233527A1 (en) Composition and methods for increasing insulin sensitivity
HK1088850B (en) Compositions for affecting weight loss

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080806